1359 Broadway
Suite 1710
New York, NY 10018
United States
212 433 3791
https://zentalis.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 124
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Kimberly Lynn Blackwell M.D. | CEO & Director | 1.17M | N/A | 1969 |
Mr. Cameron S. Gallagher M.B.A. | Co-Founder, President, Interim CFO, Interim Treasurer & Director | 892.15k | N/A | 1970 |
Ms. Andrea Paul J.D. | Chief Legal Officer & Corporate Secretary | 682.47k | N/A | 1981 |
Dr. Diana F. Hausman M.D. | Chief Medical Officer & Director | 38.44k | N/A | 1963 |
Mr. Vincent Vultaggio | VP of Finance & Interim Principal Accounting Officer | N/A | N/A | 1983 |
Dr. Mark Lackner Ph.D. | Chief Scientific Officer | N/A | N/A | 1968 |
Ms. Kimberly Freeman | Chief Strategy Officer | N/A | N/A | N/A |
Dr. Kyle Rasbach Ph.D., Pharm.D. | Chief Business Officer | N/A | N/A | 1980 |
Dr. Adrian Jubb M.D., Ph.D. | Executive Vice President of Clinical Development | N/A | N/A | N/A |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
Zentalis Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 7; Board: 5; Shareholder rights: 8; Compensation: 10.